Renaissance Capital logo

Kadmon prices IPO at $12, the low end of the range

July 26, 2016
KDMN

Kadmon Holdings, which is developing kinase inhibitors for autoimmune disease, fibrosis and solid tumors, raised $75 million by offering 6.3 million shares at $12. Kadmon Holdings plans to list on the NYSE under the symbol KDMN. Citi and Jefferies acted as lead managers on the deal.